Pillar Biosciences Incorporated · 2 months ago
Supply Chain Generalist
Natick, MA
Full-time
Onsite
New Grad, Entry Level
$60K/yr - $70K/yr
0+ years expPillar Biosciences is a company focused on developing and manufacturing targeted next-generation sequencing-based assays and software. They are seeking an entry-level Supply Chain Generalist to support supply chain operations, including generating purchase orders, tracking orders, and assisting with international customs documentation.
BiotechnologyHealth CareHealth Diagnostics
Responsibilities
Pro-actively monitor the daily re-order point report and place P.O.’s accordingly while identifying cost savings opportunities in the process
Support all internal MRO purchase requirements
Assist with picklist in support of production orders as needed
Execute daily cycle counts and report the results on a weekly basis
Monitor on time deliveries from key suppliers
Gather data and produce quarterly supplier score cards
Escalate data anomalies in a timely manner
Ensure ISO certs, supplier files and Approved Supplier List (ASL) are up to date
Assist with international documentation as needed
Report on time customer delivery data compared to forecast and customer request
Adhere to all compliance requirements
Support process automation and data integrity initiatives
Qualification
Required
Bachelor's degree
0-2 years' experience in a related role
Have the ability to generate data from excel, knowledge of pivot tables preferred
Self starter who is well organized and works with a sense of urgency
Excellent verbal and communication skills and attention to detail
Proficiency with Microsoft Office, intermediate Excel skills preferred
Must thrive in a dynamic environment and be able to pivot as necessary
Preferred
knowledge of pivot tables preferred
Proficiency with Microsoft Office, intermediate Excel skills preferred
Experience with SAP Business One is preferred
Company
Pillar Biosciences Incorporated
Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring.
51-200 employees
Funding
Current Stage
Growth StageTotal Funding
$100.4MKey Investors
ORI CapitalZhenFund
2025-05-27Series Unknown· $34.5M
2020-05-12Series C· $29.7M
2020-02-24Series Unknown· $18.03M
Leadership Team
Zhaohui Wang
Cofounder
Recent News
Morningstar.com
2025-12-11
2025-12-08
Company data provided by crunchbase